H8H-MC-LAHV: Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506253-38-00

Acronym

H8H-MC-LAHV

Enrollment

205

Registered

2024-03-22

Start date

2020-11-09

Completion date

2025-09-30

Last updated

2025-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Brief summary

Percentage of Participants with Pain Freedom (High Dose)

Interventions

DRUGPlacebo to match 100mg tablet

DRUGLasmiditan

DRUGLASMIDITAN

DRUGPlacebo to match 50mg tablet

DRUGPlacebo to match 100mg film coated tablet

DRUGPlacebo to match 25mg tablet

DRUGLasmitidan

DRUGPlacebo to match 50mg film coated tablet

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
Percentage of Participants with Pain Freedom (High Dose)	—

Countries

Belgium, France, Germany, Italy, Netherlands, Romania, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026